Genome-wide Association Study
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by Samsung Medical Center.
Recruitment status was Not yet recruiting
Information provided by (Responsible Party):
Jeeyun Lee, Samsung Medical Center
First received: December 21, 2011
Last updated: NA
Last verified: December 2011
History: No changes posted
To explore biomarkers predictive of clinical response to Taxane/5-FU/platinum based chemotherapy in esophageal squamous cell carcinoma. To identify negative predictive markers to 5-FU/platinum/Taxane. To elucidate signal transduction pathway attributable to 5-FU/platinum/Taxane resistance. To analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to Taxane/5-FU/platinum based chemotherapy.
Esophageal Squamous Cell Carcinoma.
||Observational Model: Cohort
Time Perspective: Prospective
||Genome-wide Association Study to Predict Treatment Response for Chemotherapy in Esophageal Squamous Cell Carcinoma
Primary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||June 2013 (Final data collection date for primary outcome measure)
Patients treated with Taxane/5-FU/platinum based chemo.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Esophageal squamous cell carcinoma Patients treated with Taxane/5-FU/platinum based chemotherapy.
- Histological confirmed esophageal squamous cell carcinoma
- Patients treated with Taxane or 5-FU or platinum based chemotherapy.
- provision of a signed written informed consent.
- patients not signed written informed consent.
- patient unacceptable for study in the judgement of the investigator.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01498757
Samsung Medical Center
No publications provided
||Jeeyun Lee, Professor of Medicine, Sungkyunkwan University School of Medicine, Department of Hematology and Oncology, Samsung Medical Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 21, 2011
||December 21, 2011
||Korea: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 09, 2013
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Digestive System Diseases